The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
08-Mar-04
$840 million
Target:
International Multifoods Corporation
Acquiror:
JM Smucker Company
Advised International Multifoods Corporation, whose brands include Pillsbury, Martha White, Hungry Jack and Robin Hood, on its sale to the J.M Smucker Company.
31-Mar-21
$801 million
Target:
Assets of NPC International, a former national Wendy’s and Pizza Hut franchisee
Acquiror:
Flynn Restaurant Group and a consortium of existing Wendy’s franchisees
Advised the Company on its chapter 11 proceedings and $801mm sale through a § 363 process
05-Oct-16
$775 million
Target:
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
11-Jun-20
$760 million
Target:
CSM Bakery Solutions
Acquiror:
Rhône Group
Advised the Ad-Hoc Group of First Lien and Second Lien Lenders on consensual out-of-court amend & extend
18-Mar-21
$750 million
Target:
Canopy Growth Corporation
Acquiror:
King Street Capital Management, L.P.
Advised Canopy Growth, a leading diversified cannabis company, on its US$750 million term loan financing with King Street Capital Management, L.P.
14-Nov-16
$748 million
Target:
Peacock Foods
Acquiror:
Greencore Group plc
Advised Greencore Group plc, a leading international manufacturer of convenience foods based in Ireland, on the proposed acquisition of Peacock Foods, a manufacturing partner for consumer packaged goods companies in the US.
06-Jul-12
$730 million
Target:
WMF Württembergische Metallwarenfabrik AG
Acquiror:
Kohlberg Kravis Roberts & Co. L.P.
Provided fairness opinion to the Executive Management Board of WMF in connection with the voluntary public takeover offer by Finedining Capital GmbH, a holding company in the possession of funds managed by Kohlberg Kravis Roberts & Co. L.P.
21-Nov-11
$689 million
Target:
iNova Pharmaceuticals
Acquiror:
Valeant Pharmaceuticals
Advised Archer Capital and Ironbridge Capital on the sale of iNova Pharmaceuticals, a leading pharmaceuticals company that sells and distributes a range of prescription and over-the-counter products in Australia, New Zealand, Asia and Southern Africa, to Valeant Pharmaceuticals
14-Jul-23
$674 million
Target:
Juice Plus+
Advised Juice Plus+, a global health and wellness company in the direct selling space on a comprehensive recapitalization transaction
28-Jun-16
$652 million
Target:
US rights to 37 approved and 5 pipeline generic products
Acquiror:
Mayne Pharma Group Limited
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products
30-Jun-11
$609 million
Target:
Diabetes-related patent estate and royalty stream of Astellas Pharma subsidiary, Prosidion
Acquiror:
Royalty Pharma
Advised Royalty Pharma, a leading acquiror of biopharmaceutical royalty interests, on the acquisition of the DPP-IV patent estate and associated royalty stream of Astellas Pharma subsidiary, Prosidion
10-Aug-09
$596 million
Target:
Barnes & Noble College Booksellers, Inc.
Acquiror:
Barnes & Noble, Inc.
Advised the Special Committee of the Board of Directors of Barnes & Noble, Inc., the world’s largest bookseller, on its acquisition of Barnes & Noble College Booksellers, Inc.
21-Jun-16
$586 million
Target:
US rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Impax Laboratories, Inc.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.
07-Feb-11
$548 million
Target:
Wesco Financial Corporation
Acquiror:
Berkshire Hathaway Inc.
Advised the Special Committee of Wesco Financial Corporation in connection with Berkshire Hathaway Inc.'s proposal to acquire the remaining 19.9% of the shares of Wesco’s common stock that it does not presently own
26-Jul-19
$518 million
Target:
Crossmark
Advised an ad hoc group of lenders on the comprehensive out-of-court recapitalization of Crossmark, a sales and marketing services company that provides solutions for consumer-branded suppliers and retailers
26-Mar-12
$513 million
Target:
ISTA Pharmaceuticals, Inc.
Acquiror:
Bausch + Lomb, Inc.
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its sale to Bausch + Lomb, Inc., a global ophthalmic products company
07-Dec-10
$500 million
Target:
Medicity, Inc.
Acquiror:
Aetna Inc.
Advised Aetna Inc. on its acquisition of Medicity, Inc., a leading provider of technology solutions to enable the secure access and exchange of healthcare information
13-Nov-20
$495 million
Target:
Libbey, Inc.
Acquiror:
N/A
Advised the Committee of Unsecured Creditors on the in-court restructuring of Libbey, Inc., a leading tableware manufacturer
09-Jan-17
$465 million
Target:
Palatin Technologies, Inc. lead product candidate, Rekynda
Acquiror:
AMAG Pharmaceuticals, Inc.
Advised Palatin Technologies, Inc. on the exclusive licensing of North American rights to develop and commercialize RekyndaTM (bremelanotide), an investigational product designed for on-demand treatment for hypoactive sexual desire disorder in pre-menopausal women, to AMAG Pharmaceuticals, Inc.
16-Oct-20
$430 million
Target:
Alert 360 (Central Security Group, Inc.)
Acquiror:
N/A
Advised the Ad Hoc Group of First Lien Lenders on the out-of-court restructuring of Alert 360 (Central Security Group, Inc.), a leading home-security provider
15-Jun-16
$414 million
Target:
Aegerion Pharmaceuticals
Acquiror:
QLT Inc.
Advised QLT Inc. on its merger with Aegerion Pharmaceuticals and concurrent equity raise to create a rare disease-focused global biopharmaceutical organization
17-Oct-19
$400 million
Target:
Marshall Retail Group
Acquiror:
WH Smith plc
Advised WH Smith PLC, one of the UK’s leading retailers, on the acquisition of Marshall Retail Group, a market leading US travel retailer with operations across airport, resort and tourist locations, from Brentwood Associates, a consumer-focused private equity firm
16-Nov-23
Pending
~$400 million
Target:
Sonoma-Cutrer Vineyards (Brown-Forman)
Acquiror:
The Duckhorn Portfolio
Advising Brown-Forman, the largest American-owned spirits and wine company, on its sale of Sonoma-Cutrer Vineyards to The Duckhorn Portfolio
07-Nov-11
$398 million
Target:
American Dental Partners, Inc.
Acquiror:
JLL Partners
Advised American Dental Partners, Inc. (NASD: ADPI), one of the nation’s leading business partners to dental group practices, on its sale to JLL Partners, a leading private equity firm
11-Jun-16
$350 million
Target:
US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Dr. Reddy’s Laboratories
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories